ANDEMBRY®, the first and only once-monthly treatment targeting factor XIIa to prevent attacks in HAE patients, inhibits ...

Discovered and developed in Australia by CSL scientists, ANDEMBRY is CSL’s first monoclonal antibody treatment; reinforces company’s commitment to providing a wide range of treatment ...

Featuring releases from CSL, CSL Behring, CSL Seqirus and CSL Vifor.

For additional photos, logos and other branding elements, visit Brand.csl.com and Create an Account in the External Users Only box.